Libtayo

Regeneron takes the long-haul approach to oncology, stumbles and all
Pharma Voice
Thu, 10/10/24 - 09:52 am
Regeneron
cancer
oncology
Libtayo
Regeneron hands off certain Libtayo rights in Europe to Medison Pharma
Fierce Pharma
Mon, 01/8/24 - 10:17 pm
Regeneron
Libtayo
Europe
Madison Pharma
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Wed, 11/9/22 - 10:38 am
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
BioSpace
Mon, 09/12/22 - 11:32 pm
ESMO
Regeneron
Libtayo
Regeneron completes acquisition of Sanofi’s stake in Libtayo
Pharmaceutical Business Review
Mon, 07/4/22 - 11:58 pm
Regeneron
Sanofi
Libtayo
cancer
Regeneron purchases Sanofi’s stake in Libtayo collaboration
Biopharma Reporter
Thu, 06/2/22 - 10:27 am
Regeneron
Sanofi
Libtayo
BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC
Endpoints
Tue, 03/8/22 - 10:41 am
BioNTech
Regeneron
lung cancer
vaccines
MRNA
Libtayo
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sun, 01/30/22 - 11:42 am
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Thu, 01/20/22 - 11:00 am
Regeneron
FDA
Libtayo
non-small cell lung cancer
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Sat, 10/9/21 - 11:11 pm
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Mon, 09/20/21 - 11:07 am
Sanofi
Regeneron
Libtayo
ESMO
non-small cell lung cancer
Merck
Keytruda
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
BioPharma Dive
Thu, 08/5/21 - 11:02 pm
Regeneron
Sanofi
Libtayo
clinical trials
lung cancer
Inovio is going after the 'impossible tumor' left in the dust of new cancer meds
Fierce Biotech
Fri, 05/7/21 - 10:48 am
Inovio
glioblastoma
INO-5401
INO-9012
Libtayo
clinical trials
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Mon, 03/15/21 - 10:48 am
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Mon, 02/22/21 - 11:51 pm
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Yahoo/Benzinga
Wed, 02/10/21 - 10:32 am
Sanofi
Regeneron
Libtayo
FDA
advanced basal cell carcinoma
skin cancer
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Thu, 10/29/20 - 12:17 pm
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Mon, 09/21/20 - 10:57 am
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Sanofi/Regeneron’s Libtayo set for new skin cancer use
Pharmaforum
Fri, 09/18/20 - 10:40 am
Sanofi
Regeneron
Libtayo
clinical trials
skin cancer

Pages